3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Mouth Neoplasms
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Mycosis Fungoides
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Vaccinia
1
Skin Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Sarcoma
1
Resectable Non-small Cell Lung Cancer
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Immunoblastic Lymphadenopathy
1
Interventions
pembrolizumab
16
Bevacizumab
11
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
atezolizumab
5
Standard of Care
5
Prednisone
5
Exercise
5
Cyclophosphamide
5
Cetuximab
5
durvalumab
4
abemaciclib
4
Paclitaxel
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
dostarlimab
3
daratumumab
3
cabozantinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Ipilimumab
3
Fluorouracil
3
Doxorubicin
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
cemiplimab
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled